With its novel mechanism of action and molecular design, PROTAC technology is able to overcome numerous problems of traditional small molecule inhibitors, such as high dose, side effects, drug resistance, and more. Viva's team is able to design and synthesize many different types of PROTAC molecules according to customer needs.
PROTAC project metrics across client R&D programs and internal PROTAC building block platform:
-
>40
PROTAC-based projects -
>3,500(mg up to 25 g scale)
PROTAC compounds synthesized
Available PROTAC building block metrics:
-
E3 ligase selectionCommon ligases(CRBN, VHL, MDM2, cIAP) & also underutilized ligases (FEM1B, DCAF1, RNF4, etc)
-
Linkers>300(PEG, Alkyl, Heterocycllc, Spirocycllc & conformationally restricted)
-
E3 ligase
binders>80 -
E3-linker
conjugates>300 -
POI
binders>120 -
POC kits>10
-
Pre-assembled
partial probes>200
Available E3 ligase ligand molecule types:
Available PROTAC Linker molecule types:
SMC PROTAC chemical synthesis case:
#1
#2
#3
